计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Information
Brilanestrant (GDC-0810, ARN-810) is a potentER-αbinder (ER-α, IC50 = 6.1 nM; ER-β, IC50 = 8.8 nM), a full transcriptional antagonist with no agonism and displays good potency and efficacy in ER-α degradation (EC50 = 0.7 nM) and MCF-7 breast cancer cell viability (IC50 = 2.5 nM) assays with good selectivity over other nuclear hormone receptors.
Targets
ERα (Cell-free); ERβ (Cell-free) 6.1 nM; 8.8 nM
In vitro
In cell-free radio-ligand competitive binding assays, GDC-0810 binds both ERα and ERβ with low nanomolar affinity. GDC-0810 has little to no inhibition against CYP1A2, CYP2D6, or CYP3A4 (IC50 > 20 μM), modest inhibitory effect on CYP2C9 and CYP2C19 (IC50 = 2.2 and 3.3 μM respectively), and potent inhibition of CYP2C8 (IC50 of <0.1 μM). Selectivity of GDC-0810 over other nuclear hormone receptors is also found to be good. In transcriptional reporter assays for the mineralocorticoid (MR), progesterone-A (PR-A), progesterone (PR-B), and glucocorticoid (GR) receptors, GDC-0810 has minimal activity (IC50 > 1 μM). While in binding assays, GDC-0810 displays little activity toward the androgen receptor (AR; IC50 > 4 μM) and GR (IC50 = 0.99 μM). GDC-0810-mediated ERα depletion is dependent on the 26S proteasome. GDC-0810 antagonizes ERα ligand binding domain mutants in vitro and in vivo. In cell-free E2 competitive binding assays that was used to determine the binding of GDC-0810 to ER.WT, ER.Y537S and ER.D538G ligand binding domains, GDC-0810 retains its ability to potently displace E2 from the ligand binding domain, albeit with a slightly increased IC50 (WT: 2.6 nM vs. ER.Y537S: 5.5 nM and ER.D538G: 5.4 nM). GDC-0810 can compete the PGC1α co-activator peptide off the mutated ligand binding domain, implying that GDC-0810 is capable of driving an \'active\' to \'inactive\' conformational shift of mutant ER, though with a ~five-seven fold reduction in biochemical potency compared to wild-type ER.
In vivo
The pharmacokinetic profile of GDC-0810 shows it is a low clearance molecule across species, with good bioavailability (40−60%). As would be expected for a lipophilic carboxylic acid, the compound is highly bound to plasma proteins (>99.5% across species) and has a low to moderate volume of distribution (Vss = 0.2−2.0 L/kg across species). GDC-0810 exhibits good bioavailability across species and displays robust activity in tamoxifen-sensitive and tamoxifen-resistant xenograft models of breast cancer. GDC-0810 displays mild estrogenic activity in uterine models in vitro and in vivo.
Cell Research(from reference)
Cell lines:MCF-7 cells
Incubation Time:4 h
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 苯丙素类和聚酮类 |
| 类(Class) | 芪类 |
| 亚类(Subclass) | 暂无 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 芪类 |
| 其他上位类(Alternative Parents) | 肉桂酸 苯丙烷 吲哚类 苯乙烯 氯苯类 氟苯类 芳基氯化物 芳基氟化物 吡唑类 杂芳族化合物 氮杂环化合物 羧酸 一元羧酸及其衍生物 碳氢化合物衍生物 有机氧化物 羰基化合物 有机氯化物 有机氟化物 有机氮化合物 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 芳香族杂多环化合物 - 芳基氯化物 - 芳基氟化物 - 芳基卤化物 - 氮杂环 - 吡唑 - 苯基化合物 - 苯并吡唑 - 羰基 - 羧酰胺基 - 羧酸衍生物 - 氯苯 - 肉桂醛 - 肉桂酸或其衍生物 - 氟萘 - 卤苯 - 杂芳香族化合物 - 烃衍生物 - 吲唑 - 单羧酸或其衍生物 - 单环苯基基团 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机氯化物 - 有机氟化物 - 有机卤化物 - 有机杂环化合物 - 有机氮化合物 - 有机氧化合物 - 苯基丙烷 - 吡唑 - 苯乙烯 - 苯乙烯 |
| 描述(Description) | 该化合物属于苯乙烯类有机化合物。这类化合物含有1,2-二苯基乙烯基片段。苯乙烯类(C6-C2-C6)由常见的苯丙烯(C6-C3)骨架结构衍化而来。向苯环引入一个或多个羟基可形成苯乙烯类化合物。 |
| 外部描述符(External Descriptors) | 暂无 |
| IC50 | ERβ, IC50: 8.8 nM; ERα, IC50: 6.1 nM |
|---|---|
| ALogP | 6.808 |
| hba_count | 2 |
| HBD Count | 1 |
| Rotatable Bond | 6 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 货号 |
|---|---|---|
| 分析证书 | B413858 |